Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52 in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis (EoE).1,2 

CROSSING evaluated TEZSPIRE 210 mg and 420 mg administered subcutaneously every four weeks. Treatment with TEZSPIRE achieved histologic remission for 64.8% (210 mg dose) and 68.9% (420 mg dose) of patients at week 24, compared to 3.5% of patients on placebo (p<0.001). TEZSPIRE also reduced the frequency and severity of dysphagia symptoms (difficulty swallowing) by 18.8 points (210 mg dose; p=0.049) and 22.0 points (420 mg dose, p<0.001) from baseline vs. 14.7 points on placebo, as measured by the Dysphagia Symptom Questionnaire (DSQ) score, a patient-reported outcome measure.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.